The effect of desferrioxamine on concentration and distribution of aluminum in bone. Aluminum (Al) loaded rats were injected chronically with either desferrioxamine (DFO) or saline. Six rats of each treatment group were sacrificed before and after one, three, and nine months of treatment for determination of tissue and serum Al, and for histological localization of bone Al. Urinary Al was measured during one week before sacrifice. Al loading caused significant elevations of bone (136, 14.2 rg/1iter after nine months in control and DFO-treated animals respectively). Urinary Al excretion in the DFO-treated group was increased at all times as compared to the control rats. A decrease of muscle Al occurred after one month of DFO treatment, hut no significant differences of liver and bone Al could be shown between DFO-treated rats and their controls. Al decreased to a comparable degree in all tissues of both DFO and control rats after nine months of treatment. Histomorphometric examination of the bones showed that after one and three months of treatment, significantly less Al was localized at the calcification front of DFO-treated rats compared to their controls (75.6 6.9% and 53.4
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The present study was undertaken to study the effect of DFO on Al removal of bone and other tissues in Al-loaded rats.
Methods
Aluminum loading. Male wistar rats weighing 200 to 220 g were given 20 intraperitoneal injections of a 1 mliter aluminum chloride solution containing 2 mg Al over a six week period (four times a week during the first four weeks, and two times a week during the last two weeks). The cumulative dose of Al administered to each rat was 40 mg. During the entire experiment, the rats were fed ad libitum their ordinary rat chow and they had free access to drinking water. Rat chow A04 contains 5.7 0.5 g/kg calcium and 5.7 0.6 g/kg phosphorus according to the manufacturer (UAR, Epinay France). DFO treatment. Two weeks after stopping parenteral Al administration 36 animals were randomly divided in two groups. The control group received I mliter of physiologic saline, the other group desferrioxamine, 50 mg dissolved in 1 muter saline. Saline or desferrioxamine were administered intraperitoneally thrice a week up to the moment of sacrifice.
Urine collection. Urine was obtained by housing six rats of each group in individual metabolic cages. Five consecutive 24 hr samples were collected for the determination of urinary volume, creatinine, and Al concentrations. Collections were performed after the Al loading period and after one, three, and nine months of DFO treatment. Urinary Al excretion is expressed as mg Aug creatinine and as j.rg Al/day. The urinary concentrations were calculated as the mean of the 24 hr samples in each rat. The mean of these figures for the six rats is reported.
Evalua lion of Al contamination due to the presence of unsaturated DFO in the urine. Twelve normal rats were housed in metabolic cages for three days under the same circumstances as in the experiment. To each of the recipients used for the collection of the urine of six rats, 1 muter saline containing 50 mg DFO was added. Three consecutive 24 hr samples were collected.
Collection of blood and tissues. A first collection of blood and tissues was performed in six rats two weeks after stopping the Al administration. In another series of six rats, killed after the Al loading, the Al content of the carcasses was determined. After blood sampling, the organs specified below were removed. The gastrointestinal tract was discarded to avoid con-tamination from the Al present in the feces; afterwards the rats were skinned and homogenized using a mincer. These homogenates were stored at -20°C for later Al analysis. The other animals were killed after one, three, and nine months of treatment with either DFO or saline. In these animals, there was always a lag of time of at least two days between the last injection of the DFO solution or saline and sacrifice, Blood was obtained by cardiac puncture after thoracotomy, and brain, muscle, liver, and both femurs were taken at that moment.
Histological quantitation of Al in bone. Quantitative bone histology for measurement of Al was performed on midsagittal sections of the femur head. Bone tissue was fixed in 5% buffered formalin, dehydrated and embedded in Resin Adam without prior decalcification. Six micrometer thick sections were cut using a Jung K microtome. These sections were stained with the von Kossa and the aluminon (aurine tricarboxylic acid) techniques [20] . In the procedure, Al appeared to stain as red bands at the outer edges of the mineralized bone and in the cement lines. The percentage of trabecular surface and of cement lines covered by Al was estimated by a line-intersect technique using a Zeiss eyepiece graticule. In each bone, 36 fields were examined and the means of these measurements were calculated. The means of these figures for the six rats are reported. Chemical analyses. Serum and urine Al were determined by means of flameless atomic absorption as previously described [21] . The coefficient of variation of Al determinations in serum and urine estimated by separate analysis of 6 aliquots of the same sample was found to be 4.2%. For the analysis of tissues and carcases, the EDTA extraction method of LeGendre and Alfrey was used [22, 23] . The hetween run precision of this method, estimated by separate analysis of 5 aliquots of the same bone sample, was 4.4%. Analysis of minced carcasses of control rats not receiving Al showed concentrations below 0.5 /.Lg/g dry wt, excluding Al contamination by the mincing procedure.
Creatinine was analyzed with the Jaffe method. Statistical analysis. Statistical comparisons were performed by one-tailed Student's t-tests. If the variances of the groups to be compared differed significantly, the Cochrans test was performed. For comparison of the histological results, the Mann-Whitney test was used. All statistical analyses were performed by the BALANCE program [24] . All results are expressed as mean SD.
Results
Figure 1 shows that after the loading period with Al, increased amounts of Al were found in bone, liver, and muscle. Brain concentrations, however, were not significantly different from normal values. The total carcass Al content was 106.3 9.7 zg/g dry wt, or 7.4 0.4 mg/rat when taking into account the Al content of the tissue samples analyzed separately. Table 1 summarizes the results of tissue Al concentrations in DFO treated and control rats. After one month of treatment, total bone Al still tended to increase in both DFO-treated and control rats. When compared with the initial month 0 value, however, the changes were not statistically significant. After three months of treatment the concentration again reached the initial value. A significant decrease of bone Al was only observed after nine months of treatment. There was no differ- In muscle and liver the Al content seemed to decrease gradually. Significantly lower concentrations were noticed in both groups for liver and muscle after three and nine months of treatment, respectively.
Comparison of the DFO-treated group with the control group revealed that the only difference between them was observed in muscle after one month of treatment. In none of the other tissues could a difference in Al concentration be found. Histological examination of the bone showed no evidence of osteomalacia. As shown in Figure 2 , histomorphometric measurement reveals that at time 0, 55.5 9.5% of bone trabecula were surrounded by Al positive staining. In the rats given saline for one month, this amount increased significantly to 75.6 6.9% while it remained unchanged in the DFO-treated group. After three months of DFO treatment, a significant decrease (34.8 10.6%) compared to time 0 was observed. These measurements were also significantly different from those observed in animals treated for three months with saline (52.3 10.2%). Photomicrographs (Fig. 3) show that up to one month after stopping Al administration, virtually all Al was localized at the calcification front. After three months of treatment with either DFO or saline, Al was also found within the cement lines, but upon quantitation, the number of Al-positive cement lines was identical in both groups (18 3% for both the treated and untreated animals).
Serum Al concentrations, measured after stopping the Al loading and after one, three and nine months of treatment, are given in Table 2 . It was obvious that the loading of the rats with Al resulted in markedly increased serum Al concentrations (normal value: less than 3 rg/liter). After three months of treatment serum Al decreased significantly in both groups, A further significant decrease was observed after a nine month treatment period. However, at no time during the experiment could a significant difference be shown between DFO-treated and control rats.
Urinary Al excretion (Table 3) Symbols are: * P < 0.05; ** P < 0.01 (DFO vs. control). Results are mean SD.
The mean serum creatinine after Al loading (time 0) was 0.63 0.10 mg/dliter, illustrating normal renal function. Body wt was not different in control and DFO rats as shown in Figure 4 .
Discussion
In this experiment, Al loaded rats were used since previous studies have shown that these animals provide a good model for the study of the Al intoxication syndrome [10] [11] [12] . The present study confirms that Al loading results in a marked increase of Al in serum, urine and in some tissue; both bone and liver have a high Al content, while muscle Al increases moderately. The mean brain Al content in this study was not different from non-Al loaded animals. These data on tissue accumulation of Al confirm previous animal experiments [25] . The bone Al concentrations observed here are also comparable with those found in patients with the Al intoxication syndrome [1, 9, 10, 28, 291.
An interesting part of this experiment is the evolution of tissue Al in both the DFO-treated and the control group. After stopping the Al loading, total bone Al concentration tended to increase although the changes were not statistically significant; the value then decreased significantly from the initial value to the measurement at nine months. This decrease of total hone Al is observed in both groups, indicating that even without specific treatment Al can be mobilized. Since a decrease is observed in all tissues studied, it is most likely that body burden can decrease spontaneously by slow but continuous Al excretion once the Al administration is stopped. In our study, spontaneous decreases in tissue Al were observed after three months in liver, but only after nine months had the content in both bone and muscle significantly lowered. This suggests that in animals with normal renal function, the removal of tissue Al occurs very slowly. Slow spontaneous removal of Al has also been noted in patients with parenteral, nutrition-associated Al intoxication, as well as in patients with renal failure on dialysis [30, 31] . In a patient with aluminum-related bone disease due to aluminum present in total parenteral nutrition solutions, repeated bone biopsies showed a decrease of stainable Al after 42 months and a disappearance after another 12 months [30] . In dialysis patients, spontaneous decrease of bone Al content and improvement of symptomatic bone disease required more than four years [31] .
The effect of DFO on the Al content of different tissues is unexpected. As shown in Table 1 , the only difference between the DFO and the control group was a significant fall of muscle Al content within the first month of DFO treatment. The meaning of this lowered muscle Al is not clear since further significant decreases were only noticed after nine months of treatment. Bone and liver did not differ from controls at any time of examination.
During the treatment period, we could not observe a difference between the serum Al concentration of the DFO and the control group. At first sight, this finding is at variance with studies in humans showing a consistent increase of serum Al after DFO administration [14, 15] , and a study in rabbits that showed an increase of serum At during hours following DFO administration [32] . In our rats blood was obtained at sacrifice two days after the last DFO administration. We could, therefore, have missed the DFO-induced increase of serum Al, because serum Al had already returned to its baseline concen-600 Table 3 . Urinary Al excretion in control and DFO-treated rats at the start and after I, 3 and 9 months of treatment with either saline or DFO tration. It seems also, from recent work in humans, that the increase of serum Al after DFO administration is less pronounced after some weeks of treatment [19] . The species difference, the absence of renal failure, and the fact that the first serum analyses were performed only after one month of treatment could help to explain why no increase of serum Al in the DFO-treated group could be demonstrated.
The DFO-treated rats, however, systematically excreted more Al, since compared to the controls their urinary Al excretion was larger. The average excess urinary Al in the treated group was about 10 g/day, which approximately resuits in the removal of an extra 2.7 mg over the nine month period of treatment. This amount represents about one-third of the measured body burden. The origin of this increased urinary Al excretion under DFO cannot be evaluated from our data since no difference could he evidenced between tissue concentration in treated and non-treated animals. The possibility of a contamination by unsaturated DFO excreted in the urine that takes up Al from the environment (metabolic cages, spilled food, dust, etc.) was investigated. A contamination of about 0.20 pg/day can be expected if unsaturated DFO is present in the urine. This small difference, however, cannot explain the average excess urinary Al observed in the DFO-treated group which was found to be 10 pg/day. A possible explanation is that DFO picks up Al from organs and sites not included in this study, such as the gastrointestinal tract and the peritoneal cavity. Another possibility could be that DFO increases gut absorption rather than increasing its excretion. A more detailed investigation of the effect of DFO on Al kinetics in the gastrointestinal tract could help to elucidate this point, It is noteworthy that also in Al-loaded rabbits, the Al content of different tissues does not change significantly after subchronic DFO administration [33] . In humans treated with DFO for Al intoxication, most authors except Brown et al [161 describe a fall of bone Al content [17] [18] [19] [20] . It is, therefore, possible that the mobilization of Al by DFO is different in uremics on dialysis and animals with normal renal function. Since no controlled study of the effect of DFO on tissue Al in humans on dialysis is available, the possibility of a spontaneous decrease of tissue Al in those patients cannot be excluded.
In the present study, histomorphometry reveals that in controls the percentage of trabecula covered with Al increased from 55.5 9.5% to 75.6 6.9% after one month, and returned three months after stopping Al administration to 52.3 10.2%, which was not different from the measurement at the start. Our data also show that, despite the fact that total bone Al is not different in both groups, DFO-treated rats had significantly less Al localized at the calcification front. The amount of stainable Al in the cement lines was not different in control and DFOtreated rats. Possible explanations for the selective decrease of Al at the calcification front are that in the DFO-treated rats, the DFO bound plasma Al prevents the deposition of Al at the calcification front, or that DFO is able to remove the Al from this site. Since there was no evidence of osteomalacia in our rats, no effect of DFO on bone histology could he observed. The difference between chemical and histological Al determinations has also been observed by others 19, 29, 341.
Cournot-Witmer et at showed that in patients with Al bone disease, Al could be localized at the calcification front, whereas in patients exposed to Al, but without Al bone disease, the Al was either localized in the cement lines or was not detectable, even in the presence of increased bone Al concentration [29] .
Also, using x-ray microanalysis, it has been shown that the high concentration of Al at the calcification front is at the limit of detection of the technique, and thus, that failure to detect Al at other sites does not imply its absence [35] . The effect of DFO on this localization however has not been described.
In conclusion, our data show that in Al-loaded rats, DFO treatment results in an increased urinary Al excretion and a decrease of Al localized at the calcification front of bone. It is possible that these findings in animals with normal renal excretory mechanism for Al might not apply to the situation in patients on regular dialysis therapy, where there is little or no means to rid the body of aluminum.
